When: MACD positive for 3 consecutive sessions OR close above $109.76 (10 EMA reclaimed)

Then: Permit further scale-up toward 85-90%

When: Confirmed close below $99.50/$100 on volume >30M shares OR fresh MACD expansion (histogram making new lows below -1.0 with line below -3.0)

Then: Re-evaluate to Underweight positioning

When: Confirmed close above $112.75 (50 SMA) on volume >25M shares with operating margin holding above 4.99% in Q2 FY27 print

Then: Re-evaluate to Overweight positioning

SELL 30-50% of WMT exposure in tranches (one-third at $109-$110, one-third on retest of 50 SMA), keep defensive core; widen stop to $115.73-$118.12; condition re-entry on $115.73 close above with volume or pullback to $102

• HOLD is not paralysis — for low-beta defensive mega-cap with 22.3% ROE, beta of 0.605, and fortress balance sheet, patience is the strategy; WMT holds or recovers faster when macro deteriorates
• MACD histogram of +0.02 and RSI recovery from 30 to 49 confirm bounce is weak short-covering, but weak bounce means wait for confirmation, not sell more aggressively
• Dunkin' and Subway delivery expansion is multi-quarter structural growth vector not fully priced in; claim it 'won't show up until 2027' argues for patience, not urgency to sell
• Forward PEG is ~2 (33.6x forward PE against 17% expected EPS growth), not 'absolid' 4.04; using trailing metrics overstates the bear case
• Q2 FY27 earnings catalyst is speculative bearish thesis, not confirmed setup to disappoint; pre-emptively selling 75% is gambling, not risk management
• Stop at $114.50 is only 1.4 ATR above 50 SMA ($110.84), too tight for defensive mega-cap that routinely tests MA lines; wider stop at $115.73-$118.12 (2-3 ATR) needed to avoid being shaken out on noise
• 30-50% trim in tranches is upper bound for conservative; preserves defensive ballast if macro rotates defensive or delivery thesis materializes
• Neutral Analyst's HOLD is more dangerous than SELL — asymmetric risk profile with 39x multiple and declining operating income argues for partial trim, not adding

→ vs aggressive: Stop at $114.50 only ~1.4 ATR above 50 SMA at $110.84; normal two-sigma daily movement can pierce it, especially around earnings; this is not risk management but a tight-leash directional bet

→ vs aggressive: 75% trim magnitude is 'overstated' — 30-50% in tranches is sufficient to reduce concentration risk while preserving defensive core for macro rotation

→ vs aggressive: MACD/RSI bounce being 'suspicious' doesn't support 75% trim conclusion; weak bounce means wait for confirmation, not aggressive selling

→ vs aggressive: PE of 39 and PEG of 4.04 use trailing metrics; forward PEG is ~2 (33.6x PE vs 17% EPS growth), misleading bear case framing

→ vs aggressive: Q2 FY27 being 'setup to disappoint' is circular reasoning — treating bearish thesis as fact to conclude catalyst validates it

→ vs neutral: HOLD recommendation ignores asymmetric risk: full exposure into 39x multiple with operating margin compression is more dangerous than partial trim

SELL approximately 50% of existing WMT exposure, executed in tranches through $109 to $111 zone (a third at $109, a third on push toward $110.84, final third on retest of 50 SMA with weak volume); set stop on remaining position at $115.73 to $116; redeploy proceeds into less richly valued defensive names, consumer staples, utilities, healthcare, or cash.

• SELL direction is correct based on 39x trailing earnings, three sequential quarters of operating income decline, and broken technical structure
• Recommended trim magnitude is 50% — meaningfully more than Conservative's 30-50% but less than Aggressive's 75%
• Execution should be tranched through $109 to $111 resistance zone rather than single price level at $110.84
• Stop should be widened to $115.73-$116 (~2-2.1 ATR based on ATR of 2.55), compared to Aggressive's 1.4 ATR buffer at $114.50
• Redeploy proceeds into less richly valued defensive exposure — consumer staples at lower multiples, utilities with cleaner balance sheets, or healthcare names
• Q2 FY27 earnings (November) is the pivot point but not the only catalyst; Fed meeting in September, payrolls print, and DOJ beef probe could move stock 3-5% before November
• The trim is an opportunity to improve portfolio risk-adjusted return, not just reduce single-name exposure

→ vs aggressive: Claims about short-covering are overfitted — volume of 19 to 35 million shares following 83.6 million capitulation day is not abnormal for WMT and is consistent with stabilization rather than weakness

→ vs aggressive: Q2 FY27 earnings as 'setup to disappoint' is circular reasoning — treating bearish thesis as fact and concluding catalyst will validate it; selling 75% three months before binary event is directional gambling, not risk management

→ vs aggressive: Stop at $114.50 with ATR of 2.55 provides only 1.4 ATR of buffer — too tight for a name that can move 7-9% in a single session

→ vs conservative: 30-50% trim is too conservative for actual risk — deteriorating operating income trend, negative quarterly free cash flow requiring debt issuance, premium 39x trailing multiple, and broken technical structure warrant more decisive action

→ vs conservative: 'Hold through drawdowns' framing ignores that 50 SMA collapsed from 125 to 110 in three months and 200 SMA has flattened — this is structural damage, not routine drawdown

→ vs conservative: Leaving 50-70% exposure before uncertain earnings print is itself a directional bet — quiet version of same overconfidence Aggressive Analyst displays in opposite direction

→ vs conservative: PEG calculation defense doesn't hold up — PEG of 2 on defensive retailer with declining operating income is not attractive; earnings depressed by genuine margin compression market hasn't fully discounted